# Forecast for a COVID-19 therapeutic showing a statistically significant survival benefit for the treatment group in a n>200 RCT

by Dan Sluder, Tamay Besiroglu, Juan Cambeiro, Thomas McAndrew

Jul 05, 2020

COVID-19-therapeutics

model type:	*crowdSource*
survey date:	*6/24/2020*
prediction type:	*date*
10th percentile:	*8/30/2020*
25th percentile:	*11/9/2020*
median:	*3/20/2021*
75th percentile:	*6/18/2022*
90th percentile:	*6/3/2023*
range min:	*6/14/2020*
range max:	*6/14/2023*

Participants: 16
Median: 2021-03-21
25th Percentile: 2020-11-10
75th Percentile: 2022-06-19

Background:

The Countermeasures Surveys is a six-month long research project intended to generate and aggregate predictions regarding the development of vaccines and therapeutic interventions for SARS-CoV-2 and COVID-19, respectively. We solicit predictions each month from a large team consisting of subject-matter experts as well as top generalist forecasters with established track-records in human-judgment forecasting. The methods used for prediction solicitation and aggregation are discussed in [1].

Question:

When will a COVID-19 therapeutic or therapeutics cocktail show a statistically significant survival benefit for the treatment group in a n>200 RCT?

Resolution:

Resolves as the date when the first peer-reviewed research article of a COVID-19 therapeutic or therapeutics cocktail to enroll more than 200 patients publishes a statistically significant survival benefit for the treatment group. For our purposes, "statistically significant" means that the upper bound of the 95% confidence interval of the hazard ratio for death between treated and control patients is less than 1.0. Moreover, the results would have to be statistically significant for the entire treatment group when compared to the control group in order to resolve positively. The groups should include subsamples of participants who: require ventilation, need oxygen support, and do not require respiratory support (do not necessitate ventilation or oxygen). If the hazard ratio is not reported, we will consider an alternative measure of survival benefit that is statistically significant at a 5% significance level.

Summary of Predictions:

Experts assigned a median prediction of March 2021 (80% CI: September 2020, June 2023) that a COVID-19 therapeutic or therapeutics cocktail will show a statistically significant survival benet in a N > 200 RCT. Experts Assign a probability of 6% to this occuring after June 15th, 2023.

References:

1) https://outbreak.flashpub.io/pub/outbreak-modeling-method-of-prediction-aggregation_7ad8f40a-dbf2-4e9a-a93a-9e706831525c

2) https://github.com/mcandrewlab/vaccinceAndTherapeuticsCrowd